The brief explains why the FTC believes U.S. District Court Judge Louis Sands did not make the right decision in his June 27 ruling that stated Phoebe was immune from FTC oversight, the report said.
According to the report, the brief said the district court’s ruling could “provide a roadmap for private parties wishing to bypass any antitrust scrutiny.”
The 11th Circuit Court of Appeals recently granted the FTC a temporary injunction to block Phoebe’s proposed $195 purchase of Palmyra, and the hearing on the merger is expected to take place in October.
Read the Albany Herald report on Phoebe Putney Health System and Palmyra Medical Center.
Related Articles on Phoebe-Palmyra:
Hearing on Phoebe-Palmyra Merger Delayed
Court Grants FTC Injunction to Block Phoebe Putney Purchase
FTC to Appeal Decision Allowing Acquisition of Palmyra Medical Center
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
